甘精胰岛素在2型糖尿病合并肿瘤患者围手术期的应用  

Perioperative application of glargine in type 2 diabetic patients with esophagel cancer

作　　者：倪耀军[1] 陈胜[1] 谭静[1] 李斯亭[1] 胡文[2] 

机构地区：[1]南京医科大学附属淮安市第一人民医院胸心外科,江苏省223001 [2]南京医科大学附属淮安市第二人民医院

出　　处：《江苏医药》2012年第15期1778-1780,共3页Jiangsu Medical Journal

摘　　要：目的探讨甘精胰岛素在2型糖尿病(T2DM)合并肿瘤患者围手术期应用的效果。方法 T2DM合并食管癌患者51例,随机分为甘精胰岛素组(A组,25例)和胰岛素泵组(B组,26例)。检测并比较降糖相关指标。结果 A组在血糖控制时间、治疗后日平均血糖、胰岛素日使用量、血糖波动程度和胰岛素抵抗指数、低血糖发生率方面与B组比较差异无统计学意义(P>0.05)。A组降血糖日均费用显著低于B组[(36.8±7.6)元vs.(191.7±9.2)元](P<0.05)。结论 T2DM合并肿瘤患者围术期采用甘精胰岛素可以快速、有效、安全控制血糖,日均费用显著低于胰岛素泵降糖。Objective To investigate the perioperative use of glargine in type 2 diabetic（T2DM） patients with esophagel cancer. Methods Fifty-one T2DM patients with esophagel cancer were divided into two groups of A （25 cases, perioperatively glargine injection） and B （26 cases, perioperatively insulin pump）. The criteria related to blood glucose control were examined and compared. Results The time for controlling high blood glucose, average blood glucose, insulin dosage per day, incidence of hypoglycemia homeostasis model assessment（HOMA） for insulin resistance and blood glucose fluctuations in group A were not significantly different from those in group B （P〉0. 05）. The average cost for daily controlling blood glucose was significantly lower in group A than that in group BE（36.8±7.6） yuan vs. （191.7±9.2） yuan] （P〈0.05）. Conclusion The perioperative glargine injection for controlling high blood glucose in T2DM patients with esophagel cancer is effective, rapid and safe with less cost than insulin pump.

关 键 词：甘精胰岛素 

分 类 号：R655[医药卫生—外科学]